Search

Reset

Status

Medical Condition

Displaying 1 - 2 of 2

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (LOXO-LNC-24001)

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully…
Read More

Study of Dabrafenib, Trametinib, and Navitoclax in BRAF-Mutant Melanoma and Other Solid Tumors

Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the first part (Phase I) of the study is to test the safety of navitoclax in combination with dabrafenib and trametinibat different doses to find out what effects, if any, it has on people. There will be about 18 people treated in this part of the study. The purpose of the second part of this study (Phase II) is to compare the good and bad…
Read More